Bryan Schneider, MD

Quick facts

Phase 2 pipeline

• Genomically Directed Monotherapy
  Treatment selection based on patient-specific genomic alterations to match targeted therapies with molecular drivers of disease.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Bryan Schneider, MD portfolio CI brief
• Bryan Schneider, MD pipeline updates RSS

Related

• Sector hub: All tracked pharma companies